The pipeline is filling up fast. 346 trials registered in 2025 and more than 100 already in 2026, with 127 InhBioX candidates now in Phase II and III. Infectious...

Formulation, device and manufacturing decisions need to work together, yet they are often made separately, with expertise spread across multiple suppliers. As a ...

The transition to low-global-warmingpotential (low-GWP) propellants is one of the most significant changes to pressurised metered dose inhaler (pMDI) development...

The pharmaceutical respiratory inhalation sector is entering its second major propellant transition. In response to the Montreal Protocol requirements, the first...

The inhaled medicines pipeline is changing, expanding from conventional small molecules towards proteins, peptides, nucleic acids and other complex therapeutics....